Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks under $50 to invest in. TD Cowen maintained a ...

Lilly could pay Innovent Biologics up to $9 billion in a new alliance. Elsewhere, Roche tried to assuage investor concerns about its new multiple sclerosis drug and Roivant shares surged.

The Roivant Sciences subsidiary Priovant Therapeutics has announced positive results from the Phase II BEACON study of brepocitinib in cutaneous sarcoidosis (CS).

Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript February 6, 2026 Roivant Sciences Ltd. beats earnings ...

We recently published 10 Easy Double-Digit Gainers. Roivant Sciences Ltd. (NASDAQ:ROIV) was one of the best performers last ...

As of Friday, February 06, Roivant Sciences Ltd.’s ROIV share price has surged by 17.48%, which has investors questioning if this is right time to sell.

Roivant Sciences (ROIV) upgraded to Buy on strong Phase 2 BEACON data for brepocitinib; see pipeline upside, risks, and why it’s timely—read now.

Roivant Sciences unveiled "exceptional" results Friday for its skin disease treatment, sending the biotech stock flying.

Shares of Roivant Sciences were higher after the company released positive results from a phase-two study of its brepocitinib treatment for cutaneous sarcoidosis, a skin disease. The stock rose 14% to ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (?21.6 PPriova ...

According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.

Roivant Sciences (NASDAQ:ROIV) stock surged 15% after reporting positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, showing significant clinical improvement over placebo. The company ...